Massachusetts Weekly
SEE OTHER BRANDS

The most trusted news from Massachusetts

Massachusetts Weekly: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Weekly.

Press releases published on July 2, 2025

A Legacy of Culture and Community: Cottagers' 38th Annual House Tour Returns to Martha's Vineyard

A Legacy of Culture and Community: Cottagers' 38th Annual House Tour Returns to Martha's Vineyard

OAK BLUFFS, MA, UNITED STATES, July 2, 2025 /⁨EINPresswire.com⁩/ -- The Cottagers, Inc., a seventy-year-old philanthropic organization comprised of 100 African American female homeowners on Martha’s Vineyard, proudly presents the 38th Annual House Tour, a …

Dorchester Awning Company Celebrates 125 Years as New England’s Premier Awning Manufacturer

Dorchester Awning Company Celebrates 125 Years as New England’s Premier Awning Manufacturer

A New England Original Since 1901 - Custom-Built Awnings …

Aptia Group Continues Aptia Serves Philanthropic Initiative With Urbandale, IA Garden Beautification

Aptia Group Continues Aptia Serves Philanthropic Initiative With Urbandale, IA Garden Beautification

Aptia Group employee volunteers serve Urbandale, IA community with garden beautification to give back to the local community. BOSTON, MA, UNITED STATES, July 2, 2025 /⁨EINPresswire.com⁩/ -- Aptia, a leading provider of HR and benefits solutions, continues …

8kSec Launches Free Mobile Security Challenges to Address Real-World Skills Gaps

8kSec Launches Free Mobile Security Challenges to Address Real-World Skills Gaps

Learn iOS, Android …

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, …

Mercury Selected to Improve U.S. Defense Supply Chain Resilience for Priority Domestic Microelectronics Technology

Mercury Selected to Improve U.S. Defense Supply Chain Resilience for Priority Domestic Microelectronics Technology

ANDOVER, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a technology company that delivers mission-critical processing to the edge, today announced it has been selected by the U.S. Department of Defense (DoD) …

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of …

Emerging Clinical Trial Infrastructure in the MENA Region: A Comprehensive Market Analysis

Emerging Clinical Trial Infrastructure in the MENA Region: A Comprehensive Market Analysis

Boston, July 02, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Clinical Trial Infrastructure Regional Analysis Market: Middle East and North Africa” is expected to reach $1.3 billion by the end of 2029 at a compound annual …

Financing Innovation: Proposal for Novel Adaptive Platform Trial Fund Offers New Model for ALS Drug Development

Financing Innovation: Proposal for Novel Adaptive Platform Trial Fund Offers New Model for ALS Drug Development

Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey …

SurgiBox Expands European Presence Through Strategic Partnership with Ondatec Medical in Türkiye

SurgiBox Expands European Presence Through Strategic Partnership with Ondatec Medical in Türkiye

CAMBRIDGE, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- SurgiBox, Inc., a pioneering medical technology company dedicated to bringing safe surgery to every patient, today announced a strategic partnership with Ondatec Medical, a leading medical device …

UniFirst Announces Financial Results for the Third Quarter of Fiscal 2025

UniFirst Announces Financial Results for the Third Quarter of Fiscal 2025

WILMINGTON, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- UniFirst Corporation (NYSE: UNF) (the “Company,” “UniFirst” or “we”) today reported results for its third quarter ended May 31, 2025 as compared to the corresponding period in the prior fiscal year: Q3 …

DemandScience Earns Top Rankings in Summer 2025 G2 Reports: Substantiates Investment in AI-Driven Multi-Channel B2B Marketing

DemandScience Earns Top Rankings in Summer 2025 G2 Reports: Substantiates Investment in AI-Driven Multi-Channel B2B Marketing

DANVERS, MA, July 02, 2025 (GLOBE NEWSWIRE) -- Danvers, MA – July 02, 2025 – DemandScience, a leader in B2B tech-enabled revenue marketing solutions, today announced that its solutions earned 27 awards in G2’s Summer 2025 reports. The wins across …

Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025

Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025

IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2025 financial results after …

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVID SPEAR Study Group collaborators Drs. Michael Peluso, Amy Proal, and David …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service